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EDITORIAL OPEN
The efﬁcacy and safety of inhaled corticosteroids: are we
ignoring the potential advantages of ciclesonide?
npj Primary Care Respiratory Medicine (2014) 24, Article number:
14013; doi:10.1038/npjpcrm.2014.13; published online 20 May
2014
Inhaled corticosteroids (ICS) are still the cornerstone of treatment
in asthma1 and many physicians also prescribe ICS in chronic
obstructive pulmonary disease.2,3 The introduction of ICS
in the late 1970s caused a large shift in clinical practice regarding
the treatment of asthma. Before that time asthma was considered
a disease predominantly caused by proliferation of the smooth
muscle cell and the only treatment for this was considered to be
bronchodilators. When the efﬁcacy of ICS was ﬁnally proven by
several studies,4 and ICS were introduced in primary care, the
number of deaths, hospital admissions and night-time
calls for emergency primary care services almost disappeared.
Furthermore, in many parts of the world ICS replaced the
use of regular oral corticosteroids, and with that the incidence
of severe side effects secondary to oral steroid treatment
diminished.
Since then, asthma therapy guidelines have not changed much.
The majority of asthma patients are still treated with a
combination of ICS and short- or long-acting bronchodilators.
Asthma guidelines recommend measuring asthma control and
stepping-up of therapy when patients are uncontrolled on current
therapy and stepping-down when patients are controlled.1
However, guidelines may be too conservative in that they ignore
some evidence from both mechanistic and clinical studies
regarding the development of inhaled steroids and their
effects.1
The most important factor when deciding on ICS treatment is
the balance between beneﬁt and harm of the ICS concerned.
Research over the past decades has shown that not all patients
are equal. Although some patients might experience very few
side effects from even high-dose ICS, research from Foster
et al.5 showed that, when asked, most patients mentioned several
side effects from their ‘brown inhaler’ such as hoarseness, thin skin
and disturbed vision. Measurements of patient populations by
Foster et al.5 with the Inhaled Corticosteroids Questionnaire
showed that 45% of patients reported moderate to severe
side effects due to ICS when given in a dose ⩾ 800mcg
budesonide daily.
A study from Chambers et al.6 showed that 38% of patients who
started ICS treatment subsequently stopped because of perceived
side effects. However, side effects are seldom mentioned by
patients, both in randomised controlled trials and in primary care
consultations. Possibly this is because patients hesitate to talk
about side effects because they are ashamed of discontinuing ICS
treatment following such mild (but for them troublesome) side
effects. Discontinuation of ICS is the most common cause of lack
of asthma control in mild to moderate asthma. Therefore, the
scientiﬁc community and interested clinicians should not only
follow clinical guidelines but should also be alert to new drug
developments.
Ciclesonide is an example of a new ICS that aims to reduce side
effects by activation only in the lung, with low oral and
high pulmonary deposition, high ﬁrst pass effect in the liver
and high protein binding in the bloodstream.1 Indeed, several
clinical studies have conﬁrmed these well documented claims.
Agertoft and Pedersen7 showed that ciclesonide compared to
ﬂuticasone showed no lower leg growth rate reduction whereas
ﬂuticasone did. Derom et al.8 showed that cortisol suppression of
ciclesonide was comparable with placebo whereas ﬂuticasone led
to marked cortisol suppression when both treatments were given
at dosages leading to the same level of reduction in bronchial
hyperresponsiveness. Finally, our group has shown that patients
also perceive a difference in the number and intensity of side
effects between ciclesonide and ﬂuticasone in comparable
dosages.9
The linked paper by Kuo-Chin et al.10 is an open-label, 12-week
study comparing the effect of ciclesonide (320 mcg) once daily
with budesonide (400 mcg) twice daily in a group of 150 patients
with mild to moderate well-controlled asthma (asthma control test
score ⩾ 21) who were stepped down from combination ICS/long-
acting β2-agonist therapy. Drug adherence was higher in the
ciclesonide group (76.0% vs. 58.7%, P= 0.03) than in the
budesonide group. The results of this study show that patients
had favourable results from ciclesonide (once daily) over
budesonide (twice daily) and, more importantly, fewer
patients discontinued treatment with ciclesonide than with
budesonide. More patients in the ciclesonide group (70%) were
at least satisﬁed with their treatment, compared with 47.5% of
patients in the budesonide group (P= 0.02). Unfortunately, the
authors have not reported why the patients preferred ciclesonide.
Was this because of the efﬁcacy of the drug, the way of
administering (once daily), or was the patient perceiving less
side effects? One can only guess. However, the importance of
the study lies in the withdrawal rate due to loss of asthma
control—5% in the ciclesonide group versus 27% in the
budesonide group. This might be related to the far worse
adherence in the latter group, different ICS particle sizes, or
differences in drug deposition.
Therefore, clinicians should be aware that the dosage, inhaler
type and the administration frequency, but also the choice of ICS
drug, is important in modern clinical practice. The difference
might not lie in efﬁcacy per microgram but mostly in patients’
appreciation of the balance between efﬁcacy and potentially
troublesome side effects. Ciclesonide therefore has several
advantages over the other ICS, resulting in high efﬁcacy and low
adverse events—both local and systemic—which are relevant for
clinical practice.
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